1-(4-chlorophenyl)-5-methyl-N-(phenylmethyl)-N-(thiophen-2-ylmethyl)-4-pyrazolecarboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(4-chlorophenyl)-5-methyl-N-(phenylmethyl)-N-(thiophen-2-ylmethyl)-4-pyrazolecarboxamide
• 英文别名: N-benzyl-1-(4-chlorophenyl)-5-methyl-N-(thiophen-2-ylmethyl)pyrazole-4-carboxamide
• 化学式: C₂₃H₂₀ClN₃OS
• 分子量: 421.9
• InChiKey: ZNQUQWGFIOFWNM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  66.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF<br/>[FR] INHIBITEURS D'AGRÉGATS D'ARN ASSOCIÉS À LA RÉPÉTITION DE POLYNUCLÉOTIDES ET LEURS UTILISATIONS
  申请人：VALORISATION RECH

  公开号：WO2015042685A1

  公开（公告）日：2015-04-02

  Compounds which inhibit the formation and/or accumulation of RNA foci, such as those due to polynucleotide repeats (e.g., trinucleotide repeats) are described herein. Also described herein are uses of such compounds, such as for the inhibition of the formation and accumulation such RNA foci, as well as for the treatment of polynucleotide repeat disorders (e.g., trinucleotide repeat disorders), such as myotonic dystrophy (e.g., DM1). Such compounds include compounds of formula 1, 1a, 1b, 2, 2a and (3) described herein.

  本文描述了抑制RNA斑点的形成和/或积累的化合物，例如由于多核苷酸重复（例如三核苷酸重复）而产生的斑点。本文还描述了这些化合物的用途，例如用于抑制这种RNA斑点的形成和积累，以及用于治疗多核苷酸重复疾病（例如三核苷酸重复疾病），如肌萎缩性肌无力（例如DM1）。这些化合物包括本文描述的1、1a、1b、2、2a和（3）式的化合物。
• INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF
  申请人：VALORISATION-RECHERCHE, LIMITED PARTNERSHIP

  公开号：US20160213679A1

  公开（公告）日：2016-07-28

  Compounds which inhibit the formation and/or accumulation of RNA foci, such as those due to polynucleotide repeats (e.g., trinucleotide repeats) are described herein. Also described herein are uses of such compounds, such as for the inhibition of the formation and accumulation such RNA foci, as well as for the treatment of polynucleotide repeat disorders (e.g., trinucleotide repeat disorders), such as myotonic dystrophy (e.g., DM1). Such compounds include compounds of formula 1, 1a, 1b, 2, 2a and (3) described herein.

  本文描述了抑制RNA斑点形成和/或积累的化合物，例如由多核苷酸重复（例如三核苷酸重复）引起的斑点。本文还描述了这些化合物的用途，例如用于抑制RNA斑点的形成和积累，以及用于治疗多核苷酸重复障碍（例如三核苷酸重复障碍），如肌萎缩性侧索硬化症（例如DM1）。这些化合物包括本文中描述的1、1a、1b、2、2a和（3）式的化合物。